Results 191 to 200 of about 1,466,333 (379)

Copanlisib in combination with rituximab and bendamustine for transplant‐ineligible relapsed/refractory diffuse large B‐cell lymphoma patients: Results from the phase II multicentre FIL Copa‐BR trial from Fondazione Italiana Linfomi (FIL)

British Journal of Haematology, EarlyView.
A phase II, single‐arm, multicentre trial was conducted by Fondazione Italiana Linfomi (FIL) to investigate the combination of copanlisib plus rituximab and bendamustine (copa‐BR) in transplant‐ and chimeric antigen receptor (CAR)‐T‐ineligible relapsed/refractory (R/R) diffuse large B‐cell lymphoma (DLBCL). Thirty‐seven patients were enrolled.
Mattia Novo, Pio Manlio Mirko Frascione, Alessia Castellino, Luigi Marcheselli, Samantha Deianira Dattoli, Margherita Vannucchi, Delia Rota‐Scalabrini, Alessandra Tucci, Guido Gini, Giuseppe Tarantini, Donato Mannina, Annalisa Arcari, Arcangelo Liso, Elisabetta Scarpa, Dario Marino, Michele Spina, Ausilia Gorgone, Nicola Di Renzo, Salvatrice Mancuso, Luigi Petrucci, Agostino Tafuri, Barbara Botto, Francesca Bonello, Elisa Santambrogio, Umberto Vitolo   +24 more
wiley   +1 more source

Function and mechanism of bispecific antibodies targeting SARS-CoV-2

Cell Insight
As the dynamic evolution of SARS-CoV-2 led to reduced efficacy in monoclonal neutralizing antibodies and emergence of immune escape, the role of bispecific antibodies becomes crucial in bolstering antiviral activity and suppressing immune evasion.
Zhaohui Li, Zengyuan Zhang, Steven T. Rosen, Mingye Feng   +3 more
doaj  

CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations [PDF]

, 2003
Immunostimulatory CpG oligodeoxynucleotides (ODNs) can enhance the therapeutic effect of monoclonal antibodies (mAbs) by enhancing antibody-dependent cell-mediated cytotoxicity (ADCC).
Bakker, A. (Annie), Bevaart, L., Dahle, C.E., Jansen, M.J.H. (Marco), Ojik, H.H. van, Vugt, M.J. van, Weiner, G.J., Winkel, J.G. van de   +7 more
core  

Bispecific antibody targeting of doxorubicin to carcinoembryonic antigen-expressing colon cancer cell linesin vitro andin vivo [PDF]

, 2001
C. H. J. Ford, Perry A. Osborne, Beatriz Rego, A. Mathew   +3 more
openalex   +1 more source

The anti‐CD47 antibody magrolimab with obinutuzumab and venetoclax in relapsed or refractory indolent B‐cell lymphomas

British Journal of Haematology, EarlyView.
Follicular lymphoma (FL), marginal zone lymphoma (MZL), chronic lymphocytic leukaemia (CLL) and mantle cell lymphoma (MCL) are characterized by a continuous incidence of relapse and increasing resistance to therapy. Novel immunotherapy approaches are needed.
Rahul Lakhotia, Christopher Melani, Stefania Pittaluga, Max J. Gordon, James D. Phelan, Jagan R. Muppidi, Atekelt Tadese, Sarah Evans, Elaine S. Jaffe, Louis M. Staudt, Wyndham H. Wilson, Mark Roschewski   +11 more
wiley   +1 more source

Phase I study of intravenously applied bispecific antibody in renal cell cancer patients receiving subcutaneous interleukin 2

, 1994
B. J. Kroesen, Jan Buter, D.Th. Sleijfer, René A. J. Janssen, Wta van der Graaf, TH The, L de Leij, NH Mulder   +7 more
openalex   +2 more sources

Anti-CD3/Anti-Epidermal Growth Factor Receptor-Bispecific Antibody Retargeting of Lymphocytes against Human Neoplastic Keratinocytes in an Autologous Organotypic Culture Model [PDF]

, 2002
Isabelle Renard, Delia Mezzanzanica, Silvana Canevari, Silvano Ferrini, Jacques Boniver, Philippe Delvenne, Nathalie Jacobs   +6 more
openalex   +1 more source

Bispecific nanobody® as a new pharmacological drug for the selective inhibition of Trypsin‐3

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Proteolytic balance is dysregulated in many diseases, with proteases playing critical roles in pathological pathways. A high level of Trypsin‐3 expression has been implicated as a significant mediator of tumour progression and metastasis, and this protease is associated with poor prognosis for patients in various cancers.
Melissa David, Anaïs Faihy, Corinne Rolland, Anissa Edir, Astrid Canivet, Laetitia Ligat, Mireille Sebbag, Nathalie Vergnolle, Aurélien Olichon, Céline Deraison   +9 more
wiley   +1 more source

An Engineered Mouse Model That Generates a Diverse Repertoire of Endogenous, High-Affinity Common Light Chain Antibodies

Antibodies
Bispecific antibodies have gained increasing popularity as therapeutics as they enable novel activities that cannot be achieved with monospecific antibodies.
Yinghui Rong, I-Ling Chen, Lance Larrabee, Manali S. Sawant, Germaine Fuh, Patrick Koenig   +5 more
doaj   +1 more source

Phase I clinical trial of the bispecific antibody MDX-H210 (anti-FcγRI × anti-HER-2/neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancer [PDF]

, 2003
Roland Repp, Heidi H. van Ojik, Thomas Valerius, Gerard Groenewegen, GABRIELE WIELAND, C Oetzel, Bernhard Stockmeyer, W. Becker, Michael Eisenhut, H Steininger, Yashwant M. Deo, G.H. Blijham, J. R. Kalden, Jan G. J. van de Winkel, Martin Gramatzki   +14 more
openalex   +1 more source